Insulin Action: Role of Skeletal Muscle and Insulin-Mediated Blood Flow

This study has been completed.

First Received on July 3, 2001. Last Updated on January 20, 2009 History of Changes

Sponsor:	Department of Veterans Affairs
Information provided by:	Department of Veterans Affairs
ClinicalTrials.gov Identifier:	NCT00018304

Purpose

The overall objective of this proposal is to examine the contribution of changes in total body fat, enhancement in insulin-mediated vasodilatation and enhancement in endothelium-derived nitric oxide production to the improvements in metabolic insulin action. In addition, the study will track whether these improvements are related to changes in blood pressure.

Condition	Phase
Hypertension	Phase I

Study Type:	Observational
Official Title:	Insulin Action: Role of Skeletal Muscle and Insulin-Mediated Blood Flow

Resource links provided by NLM:

MedlinePlus related topics: Diabetes Medicines High Blood Pressure

Drug Information available for: Insulin Insulin beef

U.S. FDA Resources

Further study details as provided by Department of Veterans Affairs:

Eligibility

Ages Eligible for Study:	50 Years to 75 Years
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	Yes

Criteria

Age 50 - 75 years, elevated blood pressure, BMI greater than 25 but less than 40 kg/m2

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00018304

Locations

United States, Minnesota
University of Minnesota
Minneapolis, Minnesota, United States, 55455

Sponsors and Collaborators

Department of Veterans Affairs

Investigators

Investigator:	Arthur Leon, M.D.
Investigator:	Alan Blank, M.D.

More Information

No publications provided

ClinicalTrials.gov Identifier:	NCT00018304 History of Changes
Other Study ID Numbers:	AGCG-005-98S
Study First Received:	July 3, 2001
Last Updated:	January 20, 2009
Health Authority:	United States: Federal Government

Keywords provided by Department of Veterans Affairs:

blood pressure
insulin sensitivity
blood flow

Additional relevant MeSH terms:

Hypertension
Vascular Diseases
Cardiovascular Diseases
Insulin

Hypoglycemic Agents
Physiological Effects of Drugs
Pharmacologic Actions

ClinicalTrials.gov processed this record on February 12, 2012